CYTX_ONCVO
ID CYTX_ONCVO Reviewed; 162 AA.
AC P22085;
DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT 01-JUL-1993, sequence version 2.
DT 25-MAY-2022, entry version 90.
DE RecName: Full=Onchocystatin {ECO:0000303|PubMed:1512269};
DE Short=OV17 {ECO:0000303|PubMed:12704112};
DE AltName: Full=Cysteine proteinase inhibitor OV7 {ECO:0000303|PubMed:1512269};
DE Flags: Precursor;
OS Onchocerca volvulus.
OC Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC Spirurina; Spiruromorpha; Filarioidea; Onchocercidae; Onchocerca.
OX NCBI_TaxID=6282;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL
RP STAGE, AND DISULFIDE BOND.
RC STRAIN=Savanna;
RX PubMed=1512269; DOI=10.1016/s0021-9258(18)41931-x;
RA Lustigman S., Brotman B., Huima T., Prince A.M., McKerrow J.H.;
RT "Molecular cloning and characterization of onchocystatin, a cysteine
RT proteinase inhibitor of Onchocerca volvulus.";
RL J. Biol. Chem. 267:17339-17346(1992).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 33-162.
RC STRAIN=Savanna;
RX PubMed=2052041; DOI=10.1016/0166-6851(91)90028-5;
RA Lustigman S., Brotman B., Huima T., Prince A.M.;
RT "Characterization of an Onchocerca volvulus cDNA clone encoding a genus
RT specific antigen present in infective larvae and adult worms.";
RL Mol. Biochem. Parasitol. 45:65-76(1991).
RN [3]
RP FUNCTION.
RX PubMed=12704112; DOI=10.1128/iai.71.5.2422-2429.2003;
RA Schierack P.S., Lucius R., Sonnenburg B., Schilling K., Hartmann S.;
RT "Parasite-specific immunomodulatory functions of filarial cystatin.";
RL Infect. Immun. 71:2422-2429(2003).
CC -!- FUNCTION: Cysteine protease inhibitor which inhibits members of the
CC peptidase C1 family (PubMed:1512269, PubMed:12704112). In the human
CC host, inhibits CTSL/cathepsin L and CTSS/cathepsin S and to a lesser
CC extent CTSB/cathepsin B which may cause defects in antigen processing
CC and thereby impair antigen-driven T cell proliferation
CC (PubMed:12704112). {ECO:0000269|PubMed:12704112,
CC ECO:0000269|PubMed:1512269}.
CC -!- TISSUE SPECIFICITY: Expressed in the cuticle of L3 and L4 larvae,
CC female adult, and in the eggshell of developing microfilariae.
CC {ECO:0000269|PubMed:1512269}.
CC -!- DEVELOPMENTAL STAGE: Expressed in infective larvae (L3, L4) and adult
CC stages. {ECO:0000269|PubMed:1512269}.
CC -!- SIMILARITY: Belongs to the cystatin family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; M37105; AAA29423.1; -; mRNA.
DR PIR; A43428; A43428.
DR AlphaFoldDB; P22085; -.
DR SMR; P22085; -.
DR STRING; 6282.P22085; -.
DR MEROPS; I25.031; -.
DR EnsemblMetazoa; OVOC7453; OVOC7453; WBGene00244262.
DR HOGENOM; CLU_141818_0_0_1; -.
DR OMA; QVTIWEK; -.
DR Proteomes; UP000024404; Unassembled WGS sequence.
DR GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR CDD; cd00042; CY; 1.
DR InterPro; IPR000010; Cystatin_dom.
DR InterPro; IPR046350; Cystatin_sf.
DR InterPro; IPR018073; Prot_inh_cystat_CS.
DR Pfam; PF00031; Cystatin; 1.
DR SMART; SM00043; CY; 1.
DR SUPFAM; SSF54403; SSF54403; 1.
DR PROSITE; PS00287; CYSTATIN; 1.
PE 1: Evidence at protein level;
KW Disulfide bond; Protease inhibitor; Reference proteome; Signal;
KW Thiol protease inhibitor.
FT SIGNAL 1..32
FT /evidence="ECO:0000255"
FT CHAIN 33..162
FT /note="Onchocystatin"
FT /id="PRO_0000006669"
FT REGION 30..54
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOTIF 97..101
FT /note="Secondary area of contact"
FT /evidence="ECO:0000305"
FT SITE 53
FT /note="Reactive site"
FT /evidence="ECO:0000305"
FT DISULFID 115..128
FT /evidence="ECO:0000305|PubMed:1512269"
SQ SEQUENCE 162 AA; 18415 MW; 71FC98785CB39BED CRC64;
MLTIKDGTLL IHLLLFSVVA LVQLQGAKSA RAKNPSKMES KTGENQDRPV LLGGWEDRDP
KDEEILELLP SILMKVNEQS NDEYHLMPIK LLKVSSQVVA GVKYKMDVQV ARSQCKKSSN
EKVDLTKCKK LEGHPEKVMT LEVWEKPWEN FMRVEILGTK EV